Active Pharmaceutical Walxaha (APIs) ayaa door muhiim ah ka ciyaara warshadaha dawooyinka waana aasaaska aasaasiga ah ee soo saarista dhammaan daawooyinka.
Baaxadda suuqa ee warshadaha dawooyinka Japan ayaa kaalinta labaad kaga jira Aasiya.Kor u kaca kharashka R&D ee warshadaha dawooyinka iyo sababo kale, waxa la filayaa in suuqa Japan API-yada uu ku kori doono heer aad u sarreeya oo ah 7% ilaa 8% marka la gaadho 2025. Waxa ka mid ah, shirkadaha dawooyinka ee doorka laxaadka leh ka qaatay waxa ka mid ah. Sun Pharmaceutical, Teva, Novartis International AG, Piramal Enterprises, iyo Aurobindo.
Horumarinta warshadaha dawooyinka guud ee Japan ayaa sidoo kale wajahaya caqabada sahayda madax-bannaanida ee aan ku filneyn ee alaabta ceeriin.Ku dhawaad 50% soo dejinta gudaha ee API-yada waxaa loo isticmaalaa soo saarista dawooyinka guud, iyo alaab-qeybiyeyaasha caalamiga ah ee ugu waaweyn waxay ka yimaadaan wadamada Aasiya iyo Yurub sida India, China, South Korea, Italy, Spain, Hungary iyo Germany.Si loo yareeyo ku tiirsanaanta API-yada la soo dhoofiyo, Japan waxay diiradda saareysaa meelaynta API-yada.
Sumitomo Pharmaceuticals, oo ah shirkaddii ugu horreysay ee Japan si ay u soo saarto dawooyinka kiimikada iyadoo la adeegsanayo tignoolajiyada horumarsan ee isku-dhafka dabiiciga ah, waxay qorsheyneysaa inay dhisto API-yada daawada molecule yar yar iyo warshad dhexdhexaad ah oo ku taal Oita City, Oita Prefecture.Hadafka ugu weyn ee mashruuca waa in la kordhiyo awoodda wax soo saarka API ee shirkadda si loo daboolo baahida sii kordheysa ee API-yada tayada sare leh iyo kuwa dhexdhexaadka ah.
Warshada cusub ayaa loo qorsheeyay in la hawlgeliyo bisha Sebtembar 2024. Waaxdeeda horumarinta qandaraaska iyo wax soo saarka (CDMO) waxay isticmaashaa tignoolajiyada gaarka ah si ay u soo saarto una siiso API-yada molecule yar iyo dhexdhexaadiyeyaasha shirkadaha samaynta, oo ay ogaadaan iibka ganacsiga dibadda.Baahida xooggan ee mashaariicda horumarinta dawooyinka cusub awgeed, suuqa dawooyinka adduunka ee CDMO ayaa sii waday kobac joogto ah.Waxaa lagu qiyaasaa in qiimaha ganacsi ee caalamiga ah ee daawada CDMO uu yahay ilaa 81 bilyan oo doolarka Maraykanka ah, oo u dhiganta 10 trillion yen.
Ku tiirsanaanta nidaamkeeda hubinta tayada wanaagsan iyo faa'iidooyinka maaraynta silsiladda sahayda caalamiga ah, Sumitomo Pharmaceuticals ayaa si tartiib tartiib ah u ballaarisay ganacsigeeda CDMO sannadihii la soo dhaafay waxayna ka aasaastay jago hogaamineed Japan.Dhirta ku taal Gifu iyo Okayama waxay leeyihiin awood wax soo saar yar.Awood-soo-saarka xooggan ee API-yada iyo dhexdhexaadiyeyaasha looga baahan yahay dawooyinka daweynta molecular.Shirkadda soo saarta qandaraaska dawooyinka ee Japan ee Bushu Corporation waxay heshiis iskaashi la gashay Shirkadda dawooyinka Suzuken bishii Abriil 2021 si ay u bixiso taageero horumarineed oo wax soo saar cusub shirkadaha dawooyinka xirfadleyda ah ee doonaya inay galaan suuqa Japan.Bushu wuxuu rajeynayaa inuu fuliyo heshiis iskaashi oo loogu talagalay wax soo saarka tooska ah ee gudaha ee API-yada, iyada oo la kaashanayo labada shirkadood ee dawooyinka, si loo bixiyo adeegyo maareyn hal-joojin ah oo loogu talagalay baahida dawooyinka gaarka ah, oo ay ku jiraan kor u qaadista oggolaanshaha / kuwa haysta daroogada latalinta wareejinta, soo dejinta, qiimaynta suuqa, Wax soo saarka iyo sahayda, kaydinta iyo gaadiidka lagu aaminay, qiimaynta horumarinta iyo gargaarka bukaanka iyo adeegyada kale.
Isla mar ahaantaana, Bushu Pharmaceuticals waxay si badbaado leh u gaadhsiin kartaa bukaanada inta lagu jiro habka oo dhan iyadoo la adeegsanayo nidaamka la socodka silsiladda qabow ee gaarka ah (Cubixx) ee ay samaysay Suzuken Co., Ltd. Intaa waxaa dheer, Shirkadda Dawooyinka ee Astellas ee Japan ayaa shaaca ka qaaday in sida waafaqsan Qorshaha ballaadhinta wax-soo-saarka saddexaad, saldhigga API ee soo saarista dawooyinka shaqada go'an ee lagu aasaasay Toyama, Japan Janaayo 2020 waxaa loo isticmaali doonaa in lagu soo saaro asalka Astellas Prograf's tacrolimus hydrate API.
Tacrolimus waa daawo ka hortagta oo daaweysa diidmada xubnaha ee dadka waaweyn iyo bukaanka carruurta ee helay beerka, kelyaha, wadnaha (iyo sanbabada oggolaanshaha cusub ee FDA ee 2021).
Waqtiga boostada: Jun-03-2019
